Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial

An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in cancer mouse models and data from a small clinical trial show that it appears to be active against different cancer types with a KRAS mutation.

from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2OTE5LK